AI Index / Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc. (RXRX)
Recursion is integrating AI in drug discovery through automated synthesis platforms and active learning for precision chemistry and biology. The company relies on technology-enabled drug discovery processes to enhance efficiency in identifying novel drugs. The company is leveraging technology for precision chemistry and biology, aiming to reduce the time and cost of drug development. Recursion has several partnerships, including with NVIDIA and Exscientia to enhance capabilities in generative AI for molecular design.
Loading...
Today, we have what I like to call a trifecta that is required to make impactful medicines: AI-driven biology, AI-enabled chemistry, and AI applied to clinical development.
- Najat Khan
Similar Companies in the Swift AI Index
Quotes from recursion-pharmaceuticals Executives About Artificial Intelligence and Generative AI
We are at an important inflection point. We are harnessing everything that we have built to date to do two things. Number one, translating insights into evidence—evidence that this platform, the use of AI end to end, can generate medicines that matter.
- Najat Khan
Our focus is on unlocking that value, using AI end to end consistently to generate better targets, better molecules, and advance programs faster with repeatability.
- Najat Khan
We continue to invest to ensure we are defining the standard for how AI is applied across the full life cycle of R&D.
- Najat Khan
In parallel, continuing to invest surgically in our platform grounded in areas that will enable us to have more of those proof points.
- Najat Khan
When we look across the portfolio, we are synthesizing 90% fewer compounds than what we see in industry...we are doing this two times faster, with an average of 17 months versus 42 months for industry.
- Najat Khan
Our latest oncology program milestone leveraged both physics-based approaches to understand protein flexibility and identify novel pockets, and machine learning algorithms to rapidly execute design–make–test cycles and find highly potent molecules now progressing to the next stage.
- Najat Khan
Our partnership with NVIDIA could not be any stronger.
- Najat Khan
What really matters is data that is high quality and fit for purpose, and at Recursion Pharmaceuticals, Inc., our foundation has been building high-quality data at scale, not just one type of dataset, but multimodal across the board.
- Najat Khan
We leverage our platform to figure out which patient populations should benefit most from CDK7 inhibition.
- Najat Khan
We're excited to share that we have extended our runway to early 2028.
- Najat Khan
The technical collaboration with NVIDIA continues. Some of you might have just seen we are going to be highlighted in a lightning round for NVIDIA’s upcoming GTC presentation with HyRes.
- Najat Khan
We use our generative 3D modeling efforts and machine learning to design molecules and novel scaffolds.
- Najat Khan